PharmAthene (PIP) Slammed on SparVax rPA Clinial Hold News

August 10, 2012 9:04 AM EDT Send to a Friend
PharmAthene (AMEX: PIP) shares are getting hit early Friday following news its SparVax rPA was place on clinical hold by the FDA.

Shares are down over 20 percent in early trading.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

FDA, Momentum Movers, Trader Talk

Add Your Comment